Freenome, Inc. (NASDAQ: FRNM) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $80M. The Maz Rating grades it against the other companies in its sector.
Freenome, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.82, Freenome, Inc. trades at 0.4x sales and 2.0x book value. Over the last twelve months it generated about $218M of revenue and a net loss of $47M. It runs a gross margin of 47.8%, an operating margin of -43.8% and a net margin of -50.8%. It shows return on equity of -60.3%, return on invested capital of -13.5% and a free cash flow yield of -190.4%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 12.73. Over the past 52 weeks the share price ranged from $9.71 to $17.50, with a beta of 0.35.
Freenome, Inc. does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.